Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ali Seddighzadeh"'
Autor:
Joleen T. White, Scott D. Newsome, Bernd C. Kieseier, Robert A. Bermel, Yue Cui, Ali Seddighzadeh, Serena Hung, Mary Crossman, Meena Subramanyam
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
Background: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation i
Externí odkaz:
https://doaj.org/article/218894cfb2cd433b9f87df69b742ddd1
Autor:
David J. Sas, Daniella Magen, Wesley Hayes, Hadas Shasha-Lavsky, Mini Michael, Indra Schulte, Anne-Laure Sellier-Leclerc, Jiandong Lu, Ali Seddighzadeh, Bahru Habtemariam, Tracy L. McGregor, Kenji P. Fujita, Yaacov Frishberg, Justine Bacchetta, Véronique Baudouin, Rachel Becker-Cohen, Shimrit Tzvi Behr, Efrat Ben-Shalom, Maria Berdaguer, Detlef Bockenhauer, Pierre Cochat, Martin Coenen, Carl H. Cramer, Georges Deschênes, Claire Dossier, Emilie Doye, Liat Feraru Feldman, Maximilian Hohenadel, Florentia Kaguelidou, Irina Libinson Zebegret, John C. Lieske, Anne Maisin, Dawn S. Milliner, Moran Plonsky Toder, Shirley Pollack, Aurélie Portefaix, Bruno Ranchin, Choni Rinat, Adnan Safdar, Gesa Schalk, Poyyapakkam R. Srivaths, Cheryl L. Tran, William Van't Hoff, Jenny Weinbrand-Goichberg, Irith Weissman
Publikováno v:
Genetics in Medicine. 24:654-662
Primary hyperoxaluria type 1 (PH1) is a rare, progressive, genetic disease with limited treatment options. We report the efficacy and safety of lumasiran, an RNA interference therapeutic, in infants and young children with PH1.This single-arm, open-l
Autor:
Ivan Nestorov, Shifang Liu, Ali Seddighzadeh, Yaming Hang, Jie Zhang, Aaron Deykin, Xiao Hu, Yue Cui
Publikováno v:
The Journal of Clinical Pharmacology. 57:1005-1016
Peginterferon beta-1a reduced annualized relapse rate as compared with placebo and was approved to treat multiple sclerosis patients. A population pharmacokinetic and an exposure-efficacy model were developed to establish the quantitative relationshi
Autor:
Katherine Dawson, Ivan Nestorov, Jawad Hasan, Shulian Shang, Brian Werneburg, Ali Seddighzadeh, Xiao Hu, Bjorn Sperling
Publikováno v:
British Journal of Clinical Pharmacology
Aim Subcutaneous (s.c.) peginterferon beta-1a injected once every 2 weeks and s.c. interferon beta-1a injected three times per week (Rebif®) have demonstrated efficacy in relapsing–remitting multiple sclerosis, but direct comparisons of pharmacolo
Autor:
Ali Seddighzadeh, Laura J. Balcer, Peter A. Calabresi, Serena Hung, Alexey A Boyko, Ying Zhu, Sarah Sheikh, Jean Pelletier, Bernd C. Kieseier, Aaron Deykin, Douglas L. Arnold, Shifang Liu
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Objective: To evaluate the efficacy and safety of subcutaneous peginterferon beta-1a over 2 years in patients with relapsing–remitting multiple sclerosis in the ADVANCE study. Methods: Patients were randomized to placebo or 125 µg peginterferon be
Autor:
Xiao, Hu, Yaming, Hang, Yue, Cui, Jie, Zhang, Shifang, Liu, Ali, Seddighzadeh, Aaron, Deykin, Ivan, Nestorov
Publikováno v:
Journal of Clinical Pharmacology
Peginterferon beta‐1a reduced annualized relapse rate as compared with placebo and was approved to treat multiple sclerosis patients. A population pharmacokinetic and an exposure‐efficacy model were developed to establish the quantitative relatio
Autor:
Ali Seddighzadeh, Joleen T. White, Serena Hung, Bernd C. Kieseier, Mary Crossman, Robert A. Bermel, Meena Subramanyam, Yue Cui, Scott D. Newsome
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
Background: Efficacy of interferon beta in multiple sclerosis (MS) can be dampened in patients who develop neutralizing antidrug antibodies (NAbs). Peginterferon beta1a is an interferon conjugated with a polyethylene glycol (PEG) moiety. Pegylation i
Publikováno v:
Thrombosis and Haemostasis. 99:1035-1039
SummaryDeep vein thrombosis (DVT) is a poorly understood complication of chronic kidney disease (CKD). The objective of our analysis was to profile DVT patients with and without CKD. We defined CKD as patients requiring dialysis or patients having ne
Publikováno v:
Chest. 132:554-561
Background Hospitalized patients with medical illness are especially susceptible to the development of venous thromboembolism (VTE). Methods To improve our understanding of the demographics, comorbidities, risk factors, clinical presentation, prophyl
Publikováno v:
Thrombosis and Haemostasis. 98:656-661
SummaryPatients with cancer have an increased risk of venous thromboembolism (VTE).To further define the demographics, comorbidities, and risk factors of VTE in these patients, we analyzed a prospective registry of 5,451 patients with ultrasound conf